Opportunity
22 / 100
Current score
0.38
Thesis calls
1
Active decisions
1
Recent proof-backed thesis calls
Public preview of asset-level thesis calls linked to source content, observed prices, and outcomes.
Post argues that many age-related cellular dysfunctions can be addressed broadly via cell replacement (fresh iPSC-derived cells) rather than narrowly targeting individual proteins/pathways—implying a tailwind for regenerative medicine / iPSC cell therapy platforms versus single-target drug discovery.
Mentioned: May 22, 2026, 5:02 PM EDTConviction: 38 / 100
Source: @dshahh @varma_ashwin97 Cells can be dysfunctional in many ways (with aging, that becomes more true, everything becom...
Current stance
Recommendationbuy
Authors1
Active decisions1
Latest pricen/a
Top authors on this asset
Investment decisions
IPSC
research_buyUnlock full asset monitoring
Create an account to inspect complete asset history, trust-weighted rankings, and persisted evidence across authors, theses, and market events.